Findings

What do systematic reviews say?

110 questions · 112 findings · 67 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 52 · 46.4%GRADE not reported 2 · 1.8%Very low 9 · 8%Low 13 · 11.6%Moderate 19 · 17%High 17 · 15.2%

Mepolizumab 300 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 451 participants
Moderate

Mepolizumab 100 mg vs placebo

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 911 participants
Moderate

Ruxolitinib vs placebo

Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF

Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).

1 finding from 1 review

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
RR 8.82 [4.4, 17.69]
1 study · 309 participants
Low

Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo

Self‐reported health‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) · patients with fibromyalgia

Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported health‐related quality of life (0‐100 scale) Higher… compared with placebo (low certainty).

1 finding from 1 review

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia 2018 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 6861 participants
Low

Ataluren vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 506 participants
High

Ascorbic acid vs placebo

Health‐related quality of life (mental) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 123 participants
Moderate

CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups · people with paediatric psoriasis

1 finding from 1 review

Anti‐TNF agents for paediatric psoriasis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 211 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Ascorbic acid vs placebo

Health‐related quality of life (physical) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 400 participants
Moderate

Eculizumab vs placebo

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · patients with paroxysmal nocturnal hemoglobinuria

1 finding from 1 review

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low